Shots:

• The conditional approval is based on the results of the P-II KarMMa study involves assessing Abecma in 122 patients with RRMM prior treated with 3L+ therapy including an immunomodulatory agent- a proteasome inhibitor- and an anti-CD38 Ab and who are refractory to their last treatment
• Results: @median follow-up of 13.3 mos.- ORR (74%); CR (32%); mDoR (11mos. who achieved a PR and 19 mos. who achieved a CR); median time to response (1mos.)- responses were rapid and durable with a single infusion and safety profile was generally manageable
• Abecma (idecabtagene vicleucel; ide-cel) is a one-time infusion- first BCMA CAR T cell immunotherapy for adults with MM

  Ref: Newswire.ca | Image: BMS